Pharmaceutical Technology, 10 October 2022
Communication of Site Shutdown - Hovione Macau
News release, 18 July 2022
On July 9th, 2022, the Government of the Special Administrative Region of Macau issued the Executive Order No. 115/2022 ordering all industries and commercial businesses located in Macau to suspend operations and shut down from July 11th to July 18th as an extraordinary measure to contain the spread of COVID-19 in the community. In accordance with the executive order, the majority of businesses located in Macau are obliged to shut down from 00:00 on July 11th, 2022 to 00:00 on July 23rd, 2022, including Hovione's manufacturing facility located in the territory.
Since the start of the COVID-19 epidemic, Hovione has been employing procedures and rules to reduce and minimize the impact of forced shutdowns and closures to our manufacturing facilities. Although the temporary suspension of our activities in Macau is beyond the reasonable control of Hovione and mandated by the local government, we will continue to employ all measures to reduce and mitigate the impact of such Interruption on our activities, our customers and partners.
Some of the measures employed at this facility include building up safety stocks of raw materials and finished API, advancing shipment dispatch dates to those clients facing the highest risk of disruption, leveraging bonded warehouses to allow for continued supply of materials, among others.
We commit to immediately notifying you if there are any foreseeable disruptions that may impact your product. Should you have any questions feel free to reach out to your account manager who will be happy to support you.
In the meantime, we will continue to make safe our place of work in order to continue serving our clients and our communities the best we can as we are In it for life.
Hovione is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) and is currently a fully integrated supplier offering services for drug substance, drug product intermediate and drug product. With four FDA inspected sites in the USA, China, Ireland, and Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA, the company provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs including highly potent compounds and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of and services, from API, formulation development and devices. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.